A recent study published in the New England Journal of Medicine suggests that the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar may hold significant benefits for patients diagnosed with primary biliary cholangitis. Led by Gideon M. Hirschfield, Ph.D., from the University Health Network in Toronto, the phase 3 clinical trial involved 193 patients with primary
English
French (Français)
Spanish (Español)
Arabic
Portuguese (Português)
Deutsch
Turkish (Türk)
Italiano
Romaian (Română)
Português (Brasil)
Greek (Ελληνικά)
Russian (русский)